首页>
外国专利>
PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CYCLOOXYGENASE-2 MEDIATED DISEASES, SAID COMPOSITION COMPRISING A CYCLOOXYGENASE-2 INHIBITING COMPOUND CHARACTERIZED BY HIGH POTENCY, A LONG HALF-LIFE AND A HIGH DEGREE OF SPECIFICITY FOR INHIBITING CYCLOOXYGENASE-2
PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CYCLOOXYGENASE-2 MEDIATED DISEASES, SAID COMPOSITION COMPRISING A CYCLOOXYGENASE-2 INHIBITING COMPOUND CHARACTERIZED BY HIGH POTENCY, A LONG HALF-LIFE AND A HIGH DEGREE OF SPECIFICITY FOR INHIBITING CYCLOOXYGENASE-2
This invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day administration, said composition comprising a cyclooxygenase-2 inhibiting compound characterized by high potency, a long half-life and a high degree of specificity for inhibiting cyclooxygenase-2 in preference to cyclooxygenase-1. Such a compound is exemplified 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone. In one aspect, this invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day oral administration, said composition comprising 5 to 125 mgs of the above mentioned compound. The invention is also directed to a method of treating cyclooxygenase-2 mediated diseases comprising the once a day oral administration of 5 to 125 mgs of the above-mentioned compound. The invention is also directed to the use of the above-mentioned compound in the manufacture of a medicament containing 5 to 125 mgs of said compound for once a day administration for the treatment of cyclooxygenase-2 mediated diseases.;Ovaj pronalazak je usmeren na farmaceutsku kompoziciju za tretiranje bolesti prouzrokovanih ciklooksigenazom-2, navedena kompozicija je pogodna za oralnu primenu jednom na dan, navedena kompozicija sadri jedinjenje koje inhibira ciklooksigenazu-2, koje se karakterie velikom jainom, dugakim vremenom poluraspada i visokim stepenom specifinosti za inhibiranje ciklooksigenaze-2 u odnosu na ciklooksigenazu-1. Takvo jedinjenje je dato primerom 3-fenil-4-(4-metilsulfonil)-fenil)-2-(5H)-furanona. U jednom aspektu, ovaj pronalazak je usmeren na farmaceutsku kompoziciju za tretiranje bolesti prouzrokovanih ciklooksigenazom-2, navedena kompozicija je pogodna za oralnu primenu jednom na dan, navedena kompozicija sadri 5 do 125 mg gore pomenutog jedinjenja. Pronalazak je takodje usmeren na upotrebu gore pomenutog jedinjenja u proizvodnji leka koji sadri 5 do 125 mg navedenog jedinjenja za primenu jednom na dan za tretiranje bolesti prouzrokovanih ciklooksigenazom-2.[This invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day administration, said composition comprising a cyclooxygenase-2 inhibiting compound characterized by high potency, a long half-life and a high degree of specificity for inhibiting cyclooxygenase-2 in preference to cyclooxygenase-1. Such a compound is exemplified 3-phenyl-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone. In one aspect, this invention is directed to a pharmaceutical composition for the treatment of cyclooxygenase-2 mediated diseases, said composition being suitable for once a day oral administration, said composition comprising 5 to 125 mgs of the above mentioned compound. The invention is also directed to a method of treating cyclooxygenase-2 mediated diseases comprising the once a day oral administration of 5 to 125 mgs of the above-mentioned compound. The invention is also directed to the use of the above-mentioned compound in the manufacture of a medicament containing 5 to 125 mgs of said compound for once a day administration for the treatment of cyclooxygenase-2 mediated diseases.
展开▼
机译：本发明涉及用于治疗环氧合酶-2介导的疾病的药物组合物，所述组合物适合每天给药一次，所述组合物包含抑制环氧合酶-2的化合物，其特征在于效力高，半衰期长和抑制环加氧酶-2的特异性优先于环加氧酶-1。这种化合物的例子有3-苯基-4-（4-甲基磺酰基）苯基）-2-（5H）-呋喃酮。一方面，本发明涉及用于治疗环氧合酶-2介导的疾病的药物组合物，所述组合物适合于每天一次口服给药，所述组合物包含5-125mg上述化合物。本发明还涉及治疗环氧合酶-2介导的疾病的方法，该方法包括每天一次口服5至125mg上述化合物。本发明还涉及上述化合物在制备含有5至125mg所述化合物的药物中的用途，所述药物每天一次用于治疗环氧合酶-2介导的疾病。; Ovaj pronalazak je usmeren na farmaceutsku kompoziciju za tretiranje bolesti prouzrokovanih ciklooksigenazom-2，navedena kompozicija je pogodna zaoralnu primenu jednom na dan，navedena kompozicija sadri jedinjenje koje inhibira ciklooksigenaminos sinomena-minosimenamino sinoki reme if step na ciklooksigenazu-1。 Takvo jedinjenje je dato Primerom 3-fenil-4-（4-metilsulfonil）-fenil）-2-（5H）-furanona。 U jednom aspektu，ovaj pronalazak je usmeren na farmaceutsku kompoziciju za tretiranje bolesti prouzrokovanih ciklooksigenazom-2，navedena kompozicija je pogodna zaoralnu primenu jednom na dan，navedena pompozicija sadri 5 do Pronalazak je takodje usmeren na upotrebu gore pomenutog jedinjenja u proizvodnji leka koji sadri 5 do 125 mg navedenog jedinjenja za primenu jednom na dan za tretiranje bolesti prouzrokovanih ciklooksigenazom-2。[本发明针对环氧化酶的治疗。疾病，所述组合物适合每天给药一次，所述组合物包含抑制环加氧酶-2的化合物，该化合物的特征是优先于环加氧酶-1而具有高效力，长的半衰期和高度特异性，以抑制环加氧酶-2。这种化合物的例子有3-苯基-4-（4-甲基磺酰基）苯基）-2-（5H）-呋喃酮。一方面，本发明涉及用于治疗环氧合酶-2介导的疾病的药物组合物，所述组合物适合于每天一次口服给药，所述组合物包含5-125mg上述化合物。本发明还涉及治疗环氧合酶-2介导的疾病的方法，该方法包括每天一次口服5至125mg上述化合物。本发明还涉及上述化合物在制备含有5至125mg所述化合物的药物中的用途，所述药物每天一次用于治疗环氧合酶-2介导的疾病。
展开▼
